Confirmed Faculty

Confirmed Faculty

Dr. Alfredo Aguilar

About Dr. Alfredo Aguilar

aguilarPhysician by the Universidad Mayor de San Marcos. Clinical oncologist by the Universidad Peruana Cayetano Heredia. Ex resident by the Medicine Department of the Instituto Nacional de Enfermedades Neoplásicas (Lima-Peru). Dr. Aguilar is post-graduated in clinical oncology by the National Cancer Center Hospital (Tokio – Japan). Certified in Medical Audit and Health Services from the Universidad Ricardo Palma, Master in Public Health from the Universidad San Martín de Porres, graduated from the Instituto Peruano de Administración de Empresas (IPAE) in Health Services Management. Dr. Alfredo Aguilar is a founding member and Past President of the Peruvian Society of Medical Oncology, Past President of the scientific committee of the Peruvian Society of Palliative Care. Member of the Group of Clinical Oncology Trials (GECOPERU), Member of the European Society of Medical Oncology (ESMO), Member of the American Society of Clinical Oncology (ASCO), Member of the Latin American Society of Palliative Care (ALCP), Consultant Oncologist of the Medical Committee of the AFPs Association (COMAFP) and the Superintendencia de Banca y Seguros (SBS). Dr. Aguilar is author of several scientific publications and Principal Investigator in different clinical trials, principally in Breast and Lung cancer. Nowadays Dr. Aguilar is the Scientific and Academic Director of Oncosalud-Auna, and the Director of the Research Oncology Journal “Carcinos”.

Dr. Rafael Andrade-Alegre
Santo Tomás Hospital, Panama

About Dr. Rafael Andrade-Alegre

Dr. Andrade-Alegre obtained his medical degree at the Faculty of Medicine of the University of Panama. He completed a General Surgery residency at the Hospital Santo Tomas, Panama, 1987. Then he moved to Great Britain to train in Thoracic Surgery at the Cardiothoracic Unit of the Royal Infirmary and City Hospital in Edinburgh. Once finished the residency, he returned to Santo Tomás hospital in 1991 where he became the Chief of the Thoracic Surgery Section until now.

In 2006 developed the project of the Trauma Unit where he was its first head until April 2010. In January 2012, he was appointed Dean of the Medicine Faculty, University of Columbus in Panamá City, where he served until September 30, 2013. He has a postgraduate degree in higher education from the University of Panama.

Dr. Andrade is also member of the editorial board of several medical journals and reviewer for other scientific journals. He has published more than 40 scientific articles and book chapters. He has been awarded for the presentation of papers in national and international congresses. Currently, he is the Executive Secretary of the Ibero-American Society of Thoracic Surgery.

Dr. Belisario Arango

About Dr. Belisario Arango

Biography coming soon.

Dr. Erick Arauz

About Dr. Erick Arauz

arauzBiography coming soon.

Dr. Oscar Arrieta

About Dr. Oscar Arrieta

Oscar-ArrietaOscar Arrieta is the Head of the Thoracic Oncology Unit and the Laboratory of Personalized Medicine at the Instituto Nacional de Cancerología of Mexico. Professor at the National Autonomous University of Mexico (UNAM) since 1993. Currently he is the Associate Professor of the specialty of Medical Oncology, and Professor of the course of Highly Specialization in Thoracic Oncology of UNAM.  He received his medical degree as physician and a Master in Medical Sciences at the Faculty of Medicine of the UNAM with honors. He graduated from his residency of Internal Medicine and Medical Oncology at the National Institute of Medical Sciences with honors. He conducted an observership in research in the Department of Thoracic Oncology, M.D. Anderson Cancer Center, Houston, USA. Dr. Arrieta is author and coauthor of more than 110 publications in indexed journals including the New England Journal of the Medicine, Lancet, Journal of Clinical Oncology and Annals of Oncology, , with more than 4,800 citations in the medical literature, an average impact factor of the articles in journals in English of 5.7, and an H factor of 32.  Dr. Arrieta is strongly dedicated to research; he is focused in clinical and translational medicine in the area of oncology. His research activities include the assessment of predictive and prognostic markers for the treatment of lung cancer and mesothelioma, the development of new treatment regimens for thoracic tumors and brain metastases, and the assessment of quality of life of patients with these tumors. He is actively involved in the design and coordination of clinical trials in lung cancer and is the National Coordinator of the treatment guidelines for Non-small cell lung cancer.

Dr. Carlos Barrios
Univ. of Colorado and University of Colorado Cancer Center, USA

About Dr. Carlos Barrios

Carlos H. Barrios M.D. is Professor, Department of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), in Porto Alegre, RS, Brazil. Dr. Barrios was born in Uruguay, moved to Brazil in 1974 and graduated at PUCRS Medical School in Porto Alegre in 1979. He completed his Internal Medicine training at Hospital de Clínicas, URFGS, in Porto Alegre and Jackson Memorial Hospital, University of Miami from 1980 through 1985. He had his Hematology and Oncology training at the Washington University, Barnes and Jewish Hospitals in St Louis, US. After returning to Brazil in 1990 he has been involved with student teaching and oncology fellows training at PUCRS School of Medicine. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine since 1991. He is Director of the Oncology Research Center at Hospital São Lucas, PUCRS since 1996, where he has participated in over 200 clinical research trials over the last 16 years. He is Director of the Instituto do Câncer do Sistema de Saúde Mãe de Deus since 2000. He has a strong interest in the development of international research collaboration and implementation of cooperative research infrastructures in Latin America. As such, he is cofounder and current Director of LACOG (Latin American Cooperative Oncology Group) that congregates more than 70 investigators from 14 different countries in Latin America. Has board certification in Internal Medicine (Hospital de Clínicas, UFRGS, Porto Alegre, Brazil (1980-1982) and Jackson Memorial Hospital, University of Miami, Miami, FL, US (1982-1985), and Hematology and Oncology at Barnes and Jewish Hospitals, Washington University, Saint Luis, Mo, US (1985-1988). His clinical work is concentrated in the areas of Breast Cancer, Lung Cancer and Kidney Cancer. Has numerous abstract presentations in international congresses and scientific peer reviewed publications.

Dr. Bruno Bastos
Cleveland Clinic, USA

About Dr. Bruno Bastos

Dr. Bastos received his MD in 2001 from Universidade Federal da Bahia in Salvador, Brazil, followed by postgraduate training in internal medicine at Jackson Memorial Hospital/University of Miami/VAMC, Miami.

He completed a fellowship in hematology/medical oncology at Jackson Memorial Hospital/University of Miami/VAMC, during which he investigated the role of mTOR Inhibition in overcoming cisplatin and VP-16 resistance in small cell lung cancer cells. He then completed a special fellowship in experimental therapeutics at Dana-Farber Cancer Institute during which he investigated the synergy between PPARγ ligands and platinum-based drugs and the role of mTor inhibition in combination with MEK inhibitors in the therapy of KRAS mutant tumors.

He joined the Cleveland Clinic as a staff medical oncologist in 2009.

Dr. Ada Blidner
Instituto de Biología y Medicina Experimental- CONICET, Argentina

About Dr. Ada Blidner

Ada G. Blidner started her training in immunology early on, while studying Biology at the University of Buenos Aires. She performed a four year internship at the Virology Laboratory from the Children´s Hospital “Ricardo Gutierrez”, in Buenos Aires and a 2 month practice at the GBF Biotechnology Institute, in Braunschweig, Germany, where she studied new approaches to a more efficient streptococcus pneumoniae vaccine. After graduating with a degree in Biology, she started her PhD studies at the Oncology Institute “Angel H. Roffo”, Buenos Aires, where she performed her thesis in modulating the host immune response to impair tumor growth. In 2013 she received her PhD degree of the University of Buenos Aires and started her post-doctoral position at the Immunopathology Laboratory, lead by Dr. Gabriel Rabinovich, at the Institute of Biology and Experimental Medicine, CONICET, Buenos Aires, where she started her training on glycobiology and translational medicine. She published a paper describing mechanisms of tumor immune escape in Journal of Immunology and is currently working on two projects aiming to enhance the host immune response to attack more effectively the tumor progression, and, at the same time, to develop new precision therapies in oncology. She was recently awarded with a Postdoctoral Fellowship from the Society for Immunotherapy of Cancer to support her work.

Dr. Mark Block

About Dr. Mark Block

blockDr. Block is the Chief of the Division of Thoracic Surgery for Memorial Healthcare System in Hollywood, Florida. He has been with the system for nearly twelve years. He received his college and medical school education at Yale University, and trained in General Surgery at the University of Chicago. After a research fellowship in cancer immunotherapy at the National Cancer Institute he received his training in Thoracic Surgery at Washington University in St. Louis. After completing training he served as an Assistant Professor of Surgery first at the University of California, San Francisco, and then at the Medical University of South Carolina, in Charleston, South Carolina. He left that position in 2004 to join the Memorial Healthcare System. He has published extensively on both laboratory and clinical research. His most recent contributions have been on endoscopic ultrasound for mediastinal staging and robotic lobectomy. Dr. Block is originally from Los Angeles.

Dr. Ana Botero

About Dr. Ana Botero

Biography coming soon.

Dr. Paul Bunn
Univ. of Colorado and University of Colorado Cancer Center, USA

About Dr. Paul Bunn

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center, a position he held until 2009.He is currently Distinguished Professor, Univ. of Colorado and James Dudley endowed Professor at the University. Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee. Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct lung cancer translational research and Principal Investigator for the Lung Cancer Mutation Consortium.

Dr. Christian Caglevic
Fundación Arturo López Pérez, Chile

About Dr. Christian Caglevic

Christian Caglevic is a Medical Oncologist graduated at Universidad de Chile, Postgrade in Molecular Oncology and Targeted Therapies at Universidad del Salvador, Buenos Aires, Argentina. Currently, he is Medical Oncologist at Fundación Arturo López Pérez of Santiago, Chile and Head of the Early Development of Drugs Unit at the same institution. Dr. Caglevic has been principal investigator and sub investigator in several clinical trials in solid tumors . He has several publications in solid tumors treatment but also in basic sciences. He participates in ASCO as collaborative member and is also member of ESMO, ILOGI, Sociedad Médica de Chile, IASLC, SIOG, Sociedad Chilena de Oncología Médica, Grupo Latinoamericano de Tumores Gastrointestinales. Dr Caglevic is Board Member of Ecancer Medical Science and recently reviewer of several journals as Oncotarget and Revista Médica de Chile. He was the past Director of the Latin American Symposium of Gastroenterological Cancer (SLAGO), current leader of the Latin American Consensus in Pancreatic Cancer. Dr Caglevic is also the Local Chair of the Lung Cancer Research Workshop endorsed by IASLC (Chile, april 2016).

Dr. Manuel Magallanes Maciel

About Dr. Manuel Magallanes Maciel

Biography coming soon.

Dr. Claudio Martin

About Dr. Claudio Martin

Biography coming soon.

Dr. Luis Mas Lopez

About Dr. Luis Mas Lopez

Biography coming soon.

Dr. David Carbone

About Dr. David Carbone

carboneDavid Carbone is Professor of Internal Medicine, Director of the James Thoracic Center at the OSUMC and holds the Barbara J. Bonner Chair in Lung Research. He graduated summa cum laude from Amherst College in 1977 and received an MD and a PhD in Molecular Biology and Genetics at Johns Hopkins University in 1985. He then did an Internal Medicine internship and residency at The Johns Hopkins Hospital through 1988 followed by a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. At Vanderbilt he was Professor of Medicine, Cell Biology, and Cancer Biology, and Director of the Thoracic/Head and Neck Cancer Program, Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer for 11 years and PI of the Strategic Partnering to Evaluate Cancer Signatures (SPECS) in Lung Cancer UO1 consortium. He was recruited to the Ohio State University in 2012 to direct the James Thoracic Center. His research interests, grant support and publications have been focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms. Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially using mass spectrometry-based proteomics. He has over 200 peer-reviewed publications, books and review articles, has served on several NCI grant review panels, including the clinical program project parent committee, and has continuous NCI funding since early in his career. He has served on the Board of Scientific Counselors for the NCI, and is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and President of the International Association for the Study of Lung Cancer (IASLC).

Dr. Ligia Cardona
Dominican Republic

About Dr. Ligia Cardona

Biography coming soon.

Dr. Ignacio Castellon
Memorial Cancer Institute, USA

About Dr. Ignacio Castellon

Dr. Ignacio Castellon is a board-certified doctor of radiation oncology. He attended Tulane University and the University of Miami School of Medicine before completing his radiation oncology training at the Karmanos Cancer Institute at Wayne State University, serving as Chief Resident during his final year of training. He joined the Memorial Cancer Institute in Pembroke Pines, Florida in 2010 and is an active member of the Memorial Cancer Institute lung cancer research committee. Dr. Castellon’s clinical interests include: lung cancer, breast cancer, head and neck cancer and stereotactic body radiotherapy (SBRT) in the treatment of thoracic malignancies.

Dr. Carlomagno Castillero

About Dr. Carlomagno Castillero

Biography coming soon.

Dr. Aurelio Castrellon

About Dr. Aurelio Castrellon

Aurelio B. Castrellon, MD, is a Medical Oncologist-Hematologist with board certifications in Medical Oncology, Hematology and Internal Medicine. He earned his medical degree from the Universidad de Panama School of Medicine in 2000, and completed his internship and residency in internal medicine at Jackson Memorial Hospital in association with the University of Miami/Miller School of Medicine in 2006. He completed his fellowship in hematology and medical oncology at Jackson Memorial Hospital and the University of Miami Sylvester Comprehensive Cancer Center in 2009. There, he spent most of his training working with world-renowned authorities in the treatment of breast cancer. Dr. Castrellon is the director of breast cancer research at Memorial cancer Institute in Hollywood. Florida. He has participated as a principal and co-investigator in several breast cancer treatment clinical trials. He has also published several peer reviewed articles and clinical studies in respected medical journals. He is frequently invited to national and international meetings to present on a variety of topics related to the treatment of breast cancer.

Dr. Alberto Chiappori
Moffitt Cancer Center, USA

About Dr. Alberto Chiappori

Alberto A. Chiappori, MD currently serves as Senior Member and Professor of Oncology and Medicine for the Thoracic Oncology and Tumor Biology Programs at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He has been a member of the Thoracic Oncology Program at Moffitt since 2001. Dr. Chiappori received his MD from the Universidad Peruana Cayetano Heredia in Lima, Peru. After graduation, he completed his residency at Southern Illinois University School of Medicine in Springfield, Illinois. He then went on to finish his fellowship and senior fellowship in medical oncology-hematology at Vanderbilt University School of Medicine in Nashville, Tennessee. Dr. Chiappori has been Board Certified in Medical Oncology since 1997. Dr. Chiappori has coauthored numerous articles in journals including Clinical Cancer Research, Journal of Thoracic Oncology, and Journal of Clinical Oncology. He is also an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer (IASLC).

Dr. Luis Corrales-Rodriguez
CSS – CIMCA, Costa Rica

About Dr. Luis Corrales-Rodriguez

Luis Corrales-Rodriguez, MD is a medical oncologist at Hospital San Juan de Dios (CCSS) and at the Centro de Investigación y Manejo del Cáncer (CIMCA) in San José, Costa Rica. He obtained his medical degree at the Universidad de Costa Rica and completed his Medical Oncology residency program at the same university in 2009. He then pursued a Thoracic Oncology Fellowship at Hôpital Notre-Dame from the Centre Hospitalier de l’Université de Montréal (CHUM) in Montreal, Canada. He returned to Costa Rica joining the faculty at Hospital San Juan de Dios and becoming a pre-graduate and post-graduate professor at the Universidad de Costa Rica. He is the leading investigator for Costa Rica of several international clinical trials. He is member of the Asociación Costarricense de Oncología Médica (ACOMED), Consorcio Latinoamericano para la Investigación del Cáncer de Pulmón (CLICaP), ASCO, ESMO, and IASLC. He has co-authored numerous abstracts and peer-reviewed publications. His interests include translational medicine, molecular biology, targeted therapies, and immune-oncology applied to thoracic, gastrointestinal, and breast oncology among others.

Dr. Alejandro Crismatt
Instituto Oncologico Nacional, Panama

About Dr. Alejandro Crismatt

Personal information Nationality: Panamanian Date of birth: April 16, 1977 Birthplace: Panama, Republic of Panama  Physician Registration 5676 Code: C807  Education 2000 University of Panama Panama, Panama Doctor in Medicine  2006 – 2009 Complejo Hospitalario Metropolitano “Dr. Arnulfo Arias Madrid”  Panama, Panama Specialist in Internal Medicine   2007-2010 Instituto  Nacional de Cancerologia  Mexico City Mexico Resident Oncologia Medical   Profesional Experience   2010-to date Instituto Oncologico Nacional Panama City, Panama Attending physician of service of medical oncology  2010 – to date Centro Hemato-Oncologico Paitilla Royal Center Panama City, Panama Attending physician of service of medical oncology  Languages Spanish and English  Profesional memberships Sociedad Panameña de Oncología (SPO) – Current president.

Associate Professor Mauricio Cuello
Hospital de Clínicas, Uruguay

About Dr. Mauricio Cuello

Doctor in Medicine from the Universidad de la Republica. UdelaR, Montevideo-Uruguay (2000). Specialist in Medical Oncology. Hospital de Clinicas UdelaR (2004). Fellowship in Thoraxic Oncology. Hospital germans trias i Pujol. Badalona. Barcelona. Spain (2004-2009). Clinical coordinator Department of oncology. Institut Universitari Dexeus. Barcelona. Spàin(2009-2011) .Trial Clinical Medicine at Boehringer Ingelheim. Barcelona. Spain (2009-2011). Academic activity:Associate Professor at the Department of Oncology. Hospital de Clínicas. Montevideo, Uruguay (2011-present). Research activity: Coordinator of the Uruguayan Cooperative Oncology Group GOCUR (2011-present). Director Oncology Respiratory Disease Unit at the Department of Oncology. Hospital de Clinicas. UdelaR. (2011- present). Deputy Director at the National Cancer Institute. (2015-). National Coordinator

Dr. Suzanne Dahlberg
Dana-Farber Cancer Institute, USA

About Dr. Suzanne Dahlberg

Suzanne Dahlberg is a Senior Research Scientist in the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute, where she joined the faculty in 2006. She holds a doctorate in Biostatistics from Harvard University. Her primary research focuses on clinical and translational studies in lung cancer as the primary statistician for both the ECOG-ACRIN Thoracic Committee and the Thoracic Oncology Program at Dana-Farber Cancer Institute. In those roles, she leads the design, development, monitoring, analysis and reporting of these groups’ phase I-III clinical trials, as well as their corresponding correlative and laboratory studies. She is currently a member of the Conquer Cancer Foundation/ASCO Grants Selection Committee, the NCI Thoracic Malignancy Steering Committee, the NCTN Core Correlative Sciences Committee, and the Nature journals statistical consultants group.

Dr. Jaime de la Garza
Instituto Nacional de Cancerologia-Mexico, Mexico

About Dr. Jaime de la Garza

Born: Monterrey, N.L.Mexico, Dec 12,1934.
Studies: Medical Doctor, Universidad Autónoma de Nuevo León-Monterrey, México, 1952-1958; Postgraduate in Internal Medicine and Medical Oncology in South Texas Medicine School; at San Antonio Texas. USA, 1959-1964; Mayo Clinic, Rochester, Minnesota, 1965-1966.
Distinctions: Doctor Honoris Causa granted by the Universidad Autónoma de Puebla, Doctor in Medicine-Honoris Causa., Universidad Autónoma de Nuevo León. (Monterrey N.L.)México, Distinguished Achivement Award 2014, ASCO, 50th.Annual Meeting, Chicago Ill. may 2014 “11th.Cino del Duca Award, Achievement in Cancer Research” 14 th International Congress Anti-Cancer, Feb. 4, 2003. Versailles Palace (Paris, France).
Previous Positions: Former General Director of the Instituto Nacional de Cancerología-Mexico (1993-2003), Chairmen of the International Affairs Committee of ASCO. 2004-2007.American Society of Clinical Oncology.(ASCO ) Member and founder of “Sociedad Lationamericana y del Caribe de Oncologia Medica” (SLACOM), ESMO Developing Countries Task Force. (2005)
Publications: “Inflammatory Breast Cancer” book, Editorial SPRINGER Oct.2012, “Benign Disease of the Breast” book. Editorial NOVA, Sept. 2014, Journal of Cancerology Ed. in Chief, Among others.
Societies: American Society of Clinical Oncology (ASCO) Alumni Association Mayo Graduate School of Medicine, U.of Minnesota, Soc.Latinoamericana y del Caribe de Oncologia Medica (SLACOM) Among others.

Dr. Martin Dietrich

About Dr. Martin Dietrich

dietrichMartin F. Dietrich, MD, PhD is a medical oncologist focusing on lung cancer and other malignancies of the chest at the Memorial Cancer Institute in Miami, Florida. He also holds an appointment as Assistant Professor at Florida International University. His research focuses on the design and development of novel therapies for lung cancer, including novel agents for NTRK, ALK and EGFR mutated lung cancers. He is working on the development of several new immuno-oncology agents. Dr. Dietrich received his medical degree with distinction from the University of Heidelberg, Germany with a PhD in Cancer Biology under Professor Harald zur Hausen and received his clinical training in Internal Medicine and Hematology/Oncology at the University of Texas Southwestern Medical Center in Dallas, TX. During his time at UT Southwestern, he also obtained a PhD degree in Molecular Genetics under the supervision of Drs. John Minna and Joachim Herz.

Dr. Carolyn Dresler
Consultant, USA

About Dr. Carolyn Dresler

Carolyn Dresler, MD, MPA is a former Board member for the International Association for the Study of Lung Cancer and was trained as a thoracic surgical oncologist. Her ‘day-time job’ is the Associate Director for Medical and Health Sciences for the Office of Science at the Center for Tobacco Products within the FDA. Prior to this she was the Director for the Arkansas Department of Health Tobacco Prevention and Cessation Program. Before Arkansas, she was the Head of the Group for Tobacco and Cancer at the International Agency for Research on Cancer in Lyon, France. In 2002-2003 she completed a Master in Public Administration at the Kennedy School of Government at Harvard University. Her goal is to have fewer people dying from tobacco, specifically from tobacco-caused lung cancer.

Dr. David R. Gandara
UC Davis Comprehensive Cancer Center, USA

About Dr. David R. Gandara

David R. Gandara, MD, Professor of Medicine at the University of California at Davis (UC Davis) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at the UC Davis Comprehensive Cancer Center. He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group (SWOG) trials. He is the clinical director for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is Senior Advisor, Group Chair, of SWOG and Chair of the SWOG Lung Committee1997-2015. He is a member and prior co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 300 articles, book chapters, abstracts and editorials. He is Editor-in-chief of the journal Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is an ad hoc manuscript reviewer for eight additional journals. He served as president of International Association for the Study of Lung Cancer (IASLC) from 2009 to 2011 and is on the board of directors of IASLC and was elected as treasurer in 2013. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He also is chair of the NCI-directed Lung Correlative Science Committee. After receiving his medical degree from the University of Texas Medical Branch in Galveston, Dr. Gandara was an intern and resident at the Madigan Army Medical Center in Tacoma and a fellow at the Letterman Army Medical Center Presidio of San Francisco.

Dr. Ignacio Gil Bazo

About Dr. Ignacio Gil Bazo

Dr. Gil-Bazo is MD and PhD from the University of Navarra School of Medicine in Pamplona, Spain. He is medical oncologist and associate professor in oncology, with special interest in the study and treatment of lung cancer. He completed his training as a postdoctoral research fellow at Memorial Sloan-Kettering Cancer Center in New York, NY (USA), in the Cancer Biology and Genetics Program. He received the Medical Oncology Certificate in 2012 from the European Society for Medical Oncology (ESMO). He directs the Department of Oncology at the University of Navarra and the laboratory for New Therapeutic Targets at the Center for Applied Medical Research (CIMA), with special interest in drug resistance and metastasis mechanisms in lung cancer. Dr. Gil-Bazo has also served in more than 30 clinical trials as principal investigator mainly for lung cancer, and in more than 40 trials as co-investigator. He has served as member of the editorial board for several journals and is reviewer for Cancer Research, Clinical Cancer Research, Oncotarget, Critical Reviews in Oncology and Haematology and others. He has published more than 70 articles in international indexed journals including New England Journal of Medicine, Lancet Oncology, Cancer Research, Clinical Cancer Research, Oncogene, Oncotarget, etc.

Dr. Barbara Gitlitz

About Dr. Barbara Gitlitz

Barbara-GitlitzMy research interests as an oncologist-clinical investigator is in lung cancer, Head and Neck cancer developmental therapeutics, epigenetics, immunotherapy and genomics; including new drug development and treatment of acquired resistance to genomic based treatments. I have considerable experience in clinical trial development, conduct, and the collaboration it requires between basic science researchers and clinical investigators. As such, I have experience with a broad range of clinical trial designs and I have been PI of Investigator Initiated Trials, Cooperative Group Trials (SWOG), Phase II Consortium Trials and Multisite Pharma- sponsored trials. Currently I am the Principal Investigator for the Addario Lung Cancer Medical Institute study of the Genomics of Young Lung Cancer. This is an international trial applying a novel web based enrolment schema.

Dr. Jorge Gomez

About Dr. Jorge Gomez

gomezJorge E. Gomez Is a medical oncologist specializing in the treatment of patients with lung cancer and mesothelioma. His main research interest Is the application of new therapeutics in lung cancer.He started his career as a member of the thoracic oncology service at Memorial Sloan-Kettering and is now a member of the thoracic oncology program of the Tisch Cancer Institute At the Icahn school of medicine at Mount Sinai.

Dr. Glenwood Goss

About Dr. Glenwood Goss

Glenwood-Goss- Dr. Goss graduated at the University of Witwatersrand, Johannesburg, South Africa and completed his post-graduate training at the Royal Marsden Hospital in London, England. He is a Fellow of the Royal College of Physicians and Surgeons of Canada.  Presently, he is the Medical Director of Clinical and Translational Research at The Ottawa Hospital Cancer Centre, the Director of the Lung Cancer Program at The Ottawa Hospital Cancer Centre, Chair, and Professor of Medicine at the University of Ottawa. His principal areas of research relate to investigational new cancer drugs and thoracic oncology. Dr Goss is the Chair of the Thoracic Oncology Site Committee of the Canadian Cancer Trials Group (CCTG)    He is a member of the Phase I program at The Ottawa Hospital and a member of the IND Executive Committee, CCTG. He is on the editorial board of a number of peer reviewed journals including the Journal of Clinical Lung Cancer and is a member of the publications committee of International Association for the study of Lung Cancer. He chairs the Clinical Research Executive Committee at the Ottawa Hospital Cancer Centre. His areas of interest are early cancer drug development and thoracic oncology

Dr. Jhanelle Gray

About Dr. Jhanelle Gray

Jhanelle-GrayJhanelle E. Gray, MD, is a Medical Oncologist and the Director of clinical research in the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. She received her undergraduate degree with honors from the University of Florida and her medical degree from Cornell University Medical College in New York City.  Following her internship and residency in Internal Medicine at Cornell, Dr. Gray returned to Florida and completed her Medical Oncology Fellowship at Moffitt. She is a faculty member in the Department of Thoracic Oncology at Moffitt Cancer Center where she has been practicing since 2007.  Although Dr. Gray focuses her clinical attentions on lung cancer, she is also deeply involved in clinical research. She is the lead investigator on many thoracic clinical trials especially research investigating novel drug combinations and personalized treatment to advance the fight against lung cancer. As the Director of clinical research in the Department of Thoracic Oncology, Dr. Gray directly supervises and manages 16 team members. In this role, she fosters the clinical trial development through intra- and extramural collaborations between our medical, surgical, and radiation oncologists, research scientists, pathologists, and epidemiologists in the Department of Thoracic Oncology.

Dr. Claudia Henschke

About Dr. Claudia Henschke

Biography coming soon.

Dr. Roy Herbst
Yale Comprehensive Cancer Center, Yale School of Medicine, USA

About Dr. Roy Herbst

Dr. Herbst is Ensign Professor of Medicine, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center | Smilow Cancer Hospital, New Haven, CT. He pioneered development of several next-generation targeted agents for non-small cell lung cancer, including gefitinib, erlotinib, cetuximab, and bevacizumab. He was co-leader of BATTLE-1 and co-leads the BATTLE-2 personalized medicine clinical trial program. Herbst’s laboratory work focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC, and targeting KRAS-activated pathways. It has been translated from preclinical to clinical settings in multiple Phase II and III studies. Herbst has authored or co-authored more than 300 publications appearing in prominent journals. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. He chairs the American Association of Cancer Research’s (AACR) Tobacco Task Force and is a member of the American Society of Clinical Oncology, a fellow of the American College of Physicians, and an elected member of the Association of American Physicians. He is Developmental Therapeutics Group Leader for Southwestern Oncology Group’s (SWOG) Lung Committee, principal investigator of SWOG 0819, and steering committee chair for the Lung Master Protocol. In 2015, his team at Yale was awarded a lung SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant.

Dr. Fred R. Hirsch
University of Colorado School of Medicine, USA

About Dr. Fred R. Hirsch

Fred-R.-Hirsch-HeadshotFred R. Hirsch, MD, PhD is Professor of Medicine and Pathology at the University of Colorado School of Medicine. His research interests which have spanned 25+ years include translational research, targeted therapies and early detection of lung cancer. He is studying biomarkers related to molecular targeted therapies for chemoprevention and treatment of lung cancer, focusing on biomarkers which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch’s laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe, both in lung, head and neck cancer.
Dr. Hirsch has served on NCI’s Steering Committee for Thoracic Malignancies Program (CTEP) and is also Co-Chair for Southwest Oncology Group’s (SWOG) Lung Cancer Translational Research Committee. Dr. Hirsch serves as Associate Director for the University of Colorado Cancer Center.
Dr. Hirsch currently serves as CEO of the International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer. The IASLC’s membership includes more than 5,000 lung cancer specialists in over 100 countries. Dr. Hirsch has published more than 300 peer-reviewed scientific articles.

Dr. Luis Herrera
UF Health Cancer Center and Orlando Health, USA

About Dr. Luis Herrera

Dr. Herrera completed his medical education in the University of Puerto Rico School of Medicine and his residency in general surgery at the University of Pittsburgh Medical Center. He then pursued a fellowship in Thoracic Surgery at MD Anderson Cancer Center in Houston, with a focus in thoracic oncology and minimally invasive surgery. He is now the Section Head in the Division of Thoracic Surgery at the UF Health Cancer Center and Orlando Health in Orlando Florida. He is an Affiliate Clinical Assistant Professor of Surgery at the University of Florida. His practice focuses in thoracic oncology, minimally invasive thoracic surgery with particular expertise in robotic thoracic surgery. Dr. Herrera leads an epicenter for training and technique development in robotic lobectomy for lung cancer. He also serves as the chef Quality Officer for the Cancer Program in Orlando Health.

Dr. Yariela Herrera Malo
Hospital Santo Tomas, Panama

About Dr. Yariela Herrera Malo

Dr. Yariela Herrera earned her medical doctor degree at the Panama´s University Medical School.
She completed her Internal Medicine Specialty at Hospital Santo Tomás. Later she performed her Nuclear Medicine fellowship at the School of Medicine and Health Sciences of El Colegio Mayor Nuestra Señora del Rosario, located in Bogota, Colombia. She conducted her training at La Fundación Cardioinfantil – Instituto de Cardiología and Instituto Nacional de Cancerología of Bogota (INC) and Mexico City (INCan).
Chief of Nuclear Medicine at Novalis Treatment Center in Hospital Punta Pacífica and Nuclear Medicine physician in Hospital Santo Tomás.
Dr. Herrera is a member of the Hospital Santo Tomás Research Ethics Institutional Review Board, the Society of Nuclear Medicine & Molecular Imaging and the American Society of Nuclear Cardiology.

Dr. Puneeth Iyengar
UT Southwestern Medical Center, USA

About Dr. Puneeth Iyengar

Puneeth Iyengar, M.D., Ph.D., is an Assistant Professor of Radiation Oncology at UT Southwestern Medical Center in Dallas. He earned a BS in biology from MIT, M.D./Ph.D. degrees from Albert Einstein College of Medicine in New York, and residency at MD Anderson Cancer Center in Houston. He is co-leader of the Thoracic Disease Oriented Team in the Simmons Cancer Center at UTSW, leader of the Thoracic Radiation Oncology Team, and Director of Clinical Research for the Department of Radiation Oncology. As a physician scientist, he also runs an independent laboratory with a focus on studying the role of adipose tissue in cancer cachexia. His cachexia research program has been funded by organizations including the National Lung Cancer Partnership, Lung Cancer Research Foundation, Sidney Kimmel Research Foundation, and the American Cancer Society. Dr. Iyengar is also PI on a national trial through NRG to study local therapy in the setting of limited metastatic NSCLC.

Professor, MD. Diego Kaen
Centro Oncológico Riojano, Argentina

About Dr. Diego Kaen

Biography coming soon.

Dr. Michael Kasper

About Dr. Michael Kasper

kramerDr. Kasper is a board certified Radiation Oncologist on staff at the Boca Raton Regional Hospital, where he has practiced since 1993. He holds appointments as Clinical Assistant Professor at the University of Miami, Miller School of Medicine, and Florida Atlantic University, Dept of Biomedical Science and College of Medicine. He completed his residency at the University of Florida, where he also received his medical degree. He graduated with a B.S. in Psychology from Tufts University. Dr. Kasper served as the Medical Director of the Eugene M. and Christine E. Lynn Clinical Research Center from 2003 until 2008 and is the hospital’s principal investigator for the Radiation Therapy Oncology Group (now NRG). He was appointed by Governors Bush and Crist to serve on Florida’s Cancer Control and Research Advisory Board, which he chaired from 2005 – 2008. He also served as the Hospital’s Physician Liaison for the American College of Surgeons Committee on Cancer. His clinical focus is on patient care and research in the management of rare and difficult to treat skin cancers. He has lectured throughout the U.S. and several other countries on unique radiotherapeutic techniques and brachytherapy. Dr. Kasper has been active in the community lecturing and volunteering for many organizations. He has served on the local, Division and National Boards of the American Cancer Society, as well as the ACS National Assembly. He is past President and Chairman of the Board of the Florida /Puerto Rico Division of the ACS. He has been a leading advocate for improving cancer care throughout the state by increasing research capacity and raising treatment standards. His advocacy work at the state level was instrumental in passage of Amendment 6, which made Florida workplaces smoke-free.

Dr. Robert Keith

About Dr. Robert Keith

Robert-KeithDr. Keith is a Professor of Medicine and Cancer Biology, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine.  He is the Associate Chief of Staff for Research for the VA Eastern Colorado HealthCare System.  He directs the Colorado SPORE in Lung Cancer Clinical Trials Core and is a co-investigator on multiple SPORE clinical and basic science projects.  Dr. Keith’s main research interest is lung cancer chemoprevention and he was PI of the NCI-sponsored Lung Cancer Biomarkers and Chemoprevention Consortium (LCBCC) Iloprost Chemoprevention Trial and is the PI of an ongoing VA lung cancer chemoprevention trial evaluating pioglitazone in high risk current and former smokers.  He is also the co-PI on a newly initiated chemoprevention trial examining inhaled iloprost.  He maintains an active outpatient pulmonary medicine practice and attends on the inpatient pulmonary/critical care service at the Denver VAMC.  His basic science laboratory focuses on lung cancer chemoprevention, and examines the roles of prostaglandins and PPAR gamma agonists in pre-clinical models of lung cancer.  His other research interests include screening and early detection of lung cancer and he utilizes advanced bronchoscopic techniques (including endobronchial ultrasound, autofluorescence, and electromagnetic navigation).

Dr. Maria Lim

About Dr. Maria Lim

Biography coming soon.

Dr. Gilberto Lopes
Oncoclinicas Group, Brazil

About Dr. Gilberto Lopes

Gilberto Lopes is Chief Medical and Scientific Officer for the Oncoclinicas Group, the largest Oncology provider in Latin America with 34 clinics and more than 300 physicians. He holds a concomitant position as faculty member at the Johns Hopkins University in Baltimore, Maryland. Trained in Brazil and the United States, Dr. Lopes has published more than 100 papers and book chapters in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, Lancet Oncology and Health Affairs. In addition to delivering lectures around the world, he has been an Investigator in more than 100 studies and clinical trials covering breast, gastrointestinal, genitourinary and thoracic cancers. His other main areas of interest are health economics, policy and access to cancer drugs and treatment in low and middle income countries. Dr. Lopes is currently a committee member for the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO) and Associate Editor for ASCO University and the Journal of Global Oncology. He has served as an expert for the IAEA and the WHO in official missions and advised governments, professional societies and industry partners on issues related to cancer control and treatment.

Dr. Roberto Lopez

About Dr. Roberto Lopez

Biography coming soon.

Dr. Clarissa Mathias
NOB and Hospital Português, Brazil

About Dr. Clarissa Mathias

Clarissa Mathias obtained her medical degree at the Federal University of Bahia, Brazil. She then completed her residency in Internal Medicine at the Medical College of Pennsylvania, USA, where she served as Chief Resident. She completed her Hematology and Oncology fellowship at the University of Pennsylvania, USA. In addition, Dr. Mathias completed a PhD in Internal Medicine at the Federal University of Bahia in 2005.

Currently, she is Medical Director at the Núcleo de Oncologia da Bahia, part of the Oncoclinicas Group, Brazil where she is involved in several research protocols, and is also the oncology coordinator at Hospital Português and also coordinates the Oncology Residency.

Dr. Mathias is board certified in Internal Medicine, Hematology and Oncology by the American Board of Internal Medicine and in Clinical Oncology by the Brazilian Society of Cancerology. She is also a member of several societies such as the American Society of Clinical Oncology, Brazilian Society of Cancerology and the Brazilian Society of Oncology, and has co-authored several peer-reviewed papers.

Dr. Enrique Mendoza

About Dr. Enrique Mendoza

Biography coming soon.

Dr. Raja Mudad
Sylvester Comprehensive Cancer Center-Hollywood, USA

About Dr. Raja Mudad

Dr. Mudad received his medical degree with distinction in 1989 from the American University of Beirut. He completed an internship and residency in 1992 in Internal Medicine and a fellowship in Hematology and Medical Oncology in 1995 at Duke University Medical Center in Durham, North Carolina. In 1995 Dr. Mudad joined the Tulane University faculty in New Orleans and was promoted to Associate Professor of Medicine in 2001. Dr. Mudad also served as Chief of the Section of Hematology/Oncology at the Veterans Administration Medical Center in New Orleans and Associate Chief, Section of Hematology and Medical Oncology at Tulane Medical School and Director of Hematology/Oncology Fellowship Training between 2001-2006. Dr. Mudad currently is a member of the thoracic oncology team at the Sylvester Comprehensive Cancer Center at the University of Miami. Dr Mudad’s primary interest and research is in the fields of lung and Head and Neck cancer. He has conducted several clinical trials in lung, head & neck and various other cancers.

Dr. Ana Oton
University of Colorado Cancer Center, USA

About Dr. Ana Oton

Dr. Ana B. Oton joined Eli Lilly & Company in November 2014 as the Thoracic Medical Leader for the United States in the Medical Affairs Team. Dr. Oton overseas all the late-phase thoracic drug development programs for the country in addition to the thoracic investigator-initiated programs, educational grants, and country-specific strategy for the company. In addition, Dr. Oton is Clinical Associate Professor of Medical Oncology at Denver Health Medical Center and the University of Colorado Denver and continues seeing patients in clinic. She completed her fellowship training in Hematology-Oncology at the University of Pittsburgh. In 2007, she joined the University of Colorado Denver, Division of Medical Oncology in a dual appointment with Denver Health Medical Center as medical Oncologist and Hematologist.

Professor Sai-Hong Ou
Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, USA

About Professor Sai-Hong Ou

Dr. Sai-Hong Ignatius Ou completed his MD PhD at the University of Texas Southwestern Medical Center in Dallas, Texas; his medicine residency at Duke University Medical Center, Durham, North Carolina; and his hematology-oncology fellowship training at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. Dr. Ou is board-certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. Dr. Ou joined the University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center immediately after completing his fellowship as an assistant clinical professor in 2003 and has been promoted to Clinical Professor in 2015. He has published more than 100 peer-reviewed manuscripts. Dr. Ou has been voted as one of America’s Best Doctors six years in a row since 2009.

Dr. Harvey Pass

About Dr. Harvey Pass

Harvey-PassBiography coming soon.

Dr. Luis Paz-Arez

About Dr. Luis Paz-Arez

Luis-Paz-AresLuis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), all in Madrid, Spain.   He graduated with a degree in Medicine from the Universidad Autonoma de Madrid, in 1986, and completed a PhD in 1993 at the same university. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993–1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995. Luis Paz-Ares also completed a Master’s degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa (2002–2003).   Prior to his current position, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genitourinary tumours at the University Hospital “12 de Octubre” in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).  Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 240 papers  in peer reviewed journals, as well as many book chapters, including New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and many others..  He is an active member of various scientific societies (including ASCO, ESMO, IASLC and other) and collaborative groups (European Organisation for Research and Treatment of Cancer [EORTC], the Spanish Lung Cancer Group and the International Germ Cell Cancer Collaborative Group).

Dr. Cesar Perez
University of Louisville, USA

About Dr. Cesar Perez

Dr. Cesar Perez graduated from the Medical School of the University of Panama. Did his internship at the Chicago Medical School and Internal Medicine Residency at Cleveland Clinic Florida. Participated as a research resident at the University of Chicago Pritzker School of Medicine with research focus in novel therapies for thyroid carcinomas and lung cancer. Did his Medical Oncology and Hematology Fellowship at the University of Miami Miller School of Medicine and currently works as an Assistant Professor at the University of Louisville James Graham Brown Cancer Center with clinical and research focus on molecular targeted therapies for Lung and Head and Neck Carcinomas.

Dr. Gaspar Perez Jimenez

About Dr. Gaspar Perez Jimenez

Laurie E. Gaspar, MD FASTRO, FACR, MBA Professor and Former Chair Department of Radiation Oncology University of Colorado Denver School of Medicine  Dr Gaspar completed medical school and her residency at the University of Western Ontario.  Her areas of research interest and clinical expertise include treatment of lung cancer and brain tumors using stereotactic radiosurgery, fractionated stereotactic body radiation therapy, and intensity modulated radiation therapy. Dr Gaspar is Senior Editor of Advances in Radiation Oncology and an editorial board member of Lung Cancer Frontiers and Clinical Lung Cancer. She presently serves on committees of the Southwest Oncology Group, Radiation Therapy Oncology Group, American College of Radiology, American College of Surgeons and the National Cancer Institute. She has over 160 peer reviewed publications.

Dr. Maria Pietanza

About Dr. Maria Pietanza

pietanazaDr. Cathy Pietanza is Global Director of Scientific Affairs for Oncology within the Global Center of Scientific Affairs of Merck Research Laboratories. She leads the Merck Investigator Initiated Studies Program for Oncology and assists in executing the Oncology Scientific Leadership Strategy in multiple indications, including Lung Cancer. Prior to joining Merck, Dr. Pietanza was an Assistant Attending Physician at Memorial Sloan Kettering Cancer Center on the Thoracic Oncology Service, where she led the research program in Small Cell Lung Cancer; she also held an appointment at the Weill Cornell Medical College. Dr. Pietanza received her medical degree from The State University of New York Health Science Center at Brooklyn/Downstate in Brooklyn, New York. She completed her residency at New York Presbyterian Hospital/Weill Cornell Medical Center, and fellowship at Mount Sinai School of Medicine. Dr. Pietanza has been a principal and co-principal investigator on clinical trials in small cell and non-small cell lung cancer, as well as pulmonary neuroendocrine tumors. She has coauthored numerous articles, reviews, and book chapters, and has been an invited lecturer and presenter at national and international meetings. She has been a member of IASLC since 2009, and serves on the Career Development and Faculty Committee.

Dr. Norma Graciela Pilnik, MD, PhD, MBA, B.Pharm.
Transito Caceres Hospital, Argentina

About Dr. Norma Graciela Pilnik

Dr. Pilnik holds a degree as Biochemist and as Pharmacist from the School of Chemical Science, from the National Cordoba University, 1971, 1976 respectively. She holds a degree as Medical Doctor from the School of Medical Sciences, Cordoba University 1982. She specializes in Internal Medicine, Clinical Oncology, and Clinical Hematology. She has an MBA in Health Care Management and a PhD in Medicine and Surgery, from Cordoba University. Dr. Pilnik was Adjunct Tenured Professor of General and Applied Pharmacology, and she has been Tenured Professor of Internal Medicine at the School of Medical Sciences, Cordoba University, since 2009. She is a Academic Director of the Oncology Fellowship, at the School of Medical Sciences, Cordoba University, since 2005 and currently. She is also Member of the National Board Experts Commission for University Evaluation and Accreditation (CONEAU), in the Field of Human Health. Specialty: Clinical Oncology, since 2007. She is Head of Department of Clinical Oncology at the Transito Caceres Hospital, Cordoba, Argentina. In addition to the above mentioned she is a researcher and has participated in several international clinical trials related to different oncology areas such as molecular targets and immuno-oncology.

Dr. Robert Pirker
Medical University of Vienna, Austria

About Dr. Robert Pirker

Robert Pirker is currently Professor of Medicine and Program Director for Lung Cancer at the Department of Medicine I, Medical University of Vienna, Austria. He obtained a master’s degree in Biochemistry in 1978 and his medical degree in 1979 from the University of Vienna. Robert Pirker trained in Internal Medicine, Hemato-Oncology and Nuclear Medicine at the University of Vienna. He also worked as NIH Visiting Fellow at the Laboratory of Molecular Biology (Chief: Dr. Ira Pastan), National Cancer Institute, Bethesda, MD, USA (1983-86). His research focuses on chemotherapy and targeted therapy of lung cancer, predictive factors in lung cancer, and anaemia management in patients with cancer. Robert Pirker has published more than 170 articles, reviews or book chapters. He has been an ESMO Faculty Member on Chest Tumors and a member including chair of the IASLC Education Committee. He is a current member of the IASLC Board of Directors. He was Congress President of the 8th and 14th Central European Lung Cancer Congresses and Chair of the Scientific Committee of the European Multidisciplinary Conference on Thoracic Oncology in 2009. He will be Conference President of the IASLC 17th World Conference on Lung Cancer in 2016 in Vienna, Austria.

Dr. Luis Raez
Memorial Cancer Institute (MCI) and Memorial Health Care System (MHS), USA

About Dr. Luis Raez

Luis E. Raez, MD, FACP, FCCP; is the Medical Director of Memorial Cancer Institute (MCI), he is also the Oncology Research Director of Memorial Health Care System (MHS) and Director of the Thoracic Oncology Program. He is also Clinical Associate Professor of Medicine at Florida International University (FIU) and Visiting Professor of Medicine at Cayetano Heredia University in Peru. He is also an Affiliate Associate Professor of Clinical Biomedical Science for Florida Atlantic University (FAU). He was an Associate Professor of Medicine, Epidemiology and Public Health, and a Co-Director of Thoracic Oncology at Sylvester Cancer Center/University of Miami for 10 years (2001-2011). He has expertise in medical oncology in the areas of lung cancer, and head and neck cancer. He designs phase I-III clinical trials with new chemotherapeutic agents and combinations. Dr. Raez does translational research in the areas of cancer vaccines. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America and Asia.

Dr. Suresh Ramalingam
Winship Cancer Institute of Emory University, USA

About Dr. Suresh Ramalingam

Dr. Ramalingam specializes in the treatment of lung cancer and leads a group of physicians, scientists and care providers at Emory, whose collective goals and aspirations are to improve the outcomes for every patient with lung cancer. Under Dr. Ramalingam’s leadership, Emory and the Winship Cancer Institute has brought together a world-class multi-disciplinary team for the treatment of lung cancer that excels in research and patient care. Dr. Ramalingam’s own research focus has been to develop new drugs for the treatment of lung cancer. He has led multiple phase 1, II and III clinical trials at the institutional and international levels. Dr Ramalingam serves as the Chair of the Thoracic Malignancies Committee and the Deputy Chair for Therapeutic Programs for ECOG-ACRIN, one of the four NCI-funded cancer cooperative groups that conducts research in adult cancer patients. He also serves on the Editorial Board of leading cancer journals such as the Journal of Clinical Oncology, Annals of Oncology, and Cancer. Dr Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is also a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12). Dr Ramalingam serves on several international, national and institutional committees. He has published more than 200 original manuscripts, review articles, editorials and book chapters.

Professor Eduardo Richardet
Instituto Oncológico de Córdoba, Argentina

About Professor Eduardo Richardet

MD PHD Professor. Director of the Medical Oncology Major and Professor of Medical Oncology at UCC (Catholic University of Córdoba). Scientific Director and former President at FLASCA (Latin American Federation of Cancerology Societies). Past President of the Argentinean Society of Medical Oncology. Past Presient of Córdoba Medical Oncology Society. Past member of the International Affairs Committee at ASCO. IASCLC Regent for Latin America. JTO Associate Editor. Principal researcher in 70 clinical studies. More than 200 publication in national and international journals.

Dr. Martin Richardet

About Dr. Martin Richardet

MD PHD Professor. Director of the Medical Oncology Major and Professor of Medical Oncology at UCC (Catholic University of Córdoba). Scientific Director and former President at FLASCA (Latin American Federation of Cancerology Societies). Past President of the Argentinean Society of Medical Oncology. Past Presient of Córdoba Medical Oncology Society. Past member of the International Affairs Committee at ASCO. IASCLC Regent for Latin America. JTO Associate Editor. Principal researcher in 70 clinical studies. More than 200 publication in national and international journals.

Dr. Jorge Rios
University of Louisville, USA

About Dr. Jorge Rios

Dr Rios focuses on the treatment and care of patients with Lung Cancer and other thoracic malignancies, as part of the Multi-disciplinary Lung and Thoracic Malignancies team at the University of Louisville Cancer Center. His research focus is on developing innovative strategies aimed to overcome the barriers that are currently preventing many patients to benefit from both already available effective treatments and from therapies under study that might be available in the future. He is one of the investigators of the Kentucky LEADS (Lung Cancer Education, Awareness, Detection and Survivorship) Collaborative, a first-of-its-kind project that brings together an interdisciplinary team of community partners, lung cancer specialists and cancer prevention and control experts to assess novel approaches for reducing the burden of lung cancer in the state of Kentucky, US. He also conducts NCI-funded cooperative group trials and industry-sponsored trials.

Dr. Luis Leonardo Rojas

About Dr. Luis Leonardo Rojas

Doctor Luis Leonardo Rojas Puentes is a Medical Oncologist, obtained his fellowship from National Cancer Institute of México in 2014 and is working at Centro Javeriano de Oncología, Hospital Universitario San Ignacio in Bogotá Colombia as a medical oncologist and also he is Hematology/Oncology division director in this oncology centre. Dr Rojas also works as Assistant Professor in the Faculty of Medicine at Pontificia Universidad Javeriana in Bogotá, Colombia, participating in academic activities in medical oncology. Since few years ago Dr Rojas is involved in translational and clinical oncology research mainly focused on gastrointestinal and thoracic malignancies. He is author of several articles in local and peer review journals and also he has participated enthusiastically in LALCA and World Lung Cancer meetings as a presenter of posters related with immunologic response in lung cancer, BIM deletion polymorphisms and experiences with chemotherapy regimen based on platinum-bevacizumab in metastatic lung cancer. Dr Rojas has received distinctions for his academic and research activities from Counquer Cancer Foundation, Union for International Cancer Control (UICC) and academic institutions in México and Colombia. Dr Rojas is also involved as a colaborator of The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) a collaborative group for research in Lung Cancer around Latin American Countries.

Professor Christian Rolfo
University Hospital Antwerp, Belgium

About Dr. Professor Christian Rolfo

Prof. Dr. Christian Rolfo, MD,PhD,MBAh (Cordoba, Argentina), is board certified oncologist by University of Milan, Italy; and PhD in Clinical and Experimental Oncology (thesis on EGFR ). He has worked at Spanish Group for Lung Cancer, with Prof. Rafael Rosell, actively involved in studies of molecular biology and clinical research in NSCLC.. He has completed his training in Phase I program at MD Anderson, Texas, USA. He is the Head of Phase I – Early Clinical Trails at Antwerp University Hospital in Belgium, and Professor in Oncology at Palermo University, Italy. Prof. Rolfo was also appointed in 2012 Director of Clinical Trails Management Program in Oncology and Director of “Investigational Cancer Therapeutics Fellowship and Drug Development: Clinical and Experimental” at Antwerp University Hospital. He is working in Translational Research & Drug Development. He is also working on Liquid Biopsies in Lung Cancer (exosomes and ctDNA) He is the author of numerous papers published in worldwide prestigious journals including New England Journal of Medicine, Lancet Oncology, Oncotarget, JCO, Lung Cancer, among others. Prof. Rolfo is currently part of the educational committee of IALSC and the membership committee of ESMO. He is Section Editor of Investigational Therapeutics in CROH and in the BJMO.

Dr. Ricardo Santos
Hospital Israelita Albert Einstein, Brazil

About Dr. Ricardo Santos

Dr. Santos received his medical degree from the Federal University of Bahia in Brazil, and completed his surgical residency at the State University of Campinas, Sao Paulo, Brazil, and also research and clinical fellowships in general thoracic surgery and lung transplantation at the University of Pittsburgh Medical Center (Pennsylvania, USA). Until 2010, he was as an Instructor in Minimally Invasive CT surgery at Boston Medical Center, and faculty at the Boston University School of Medicine (BUSM, Massachusetts, USA).

From 2010 to 2014, Dr. Santos was the Head of Minimally Invasive Thoracic and Robotic Surgery at Albert Einstein Israeli Hospital (São Paulo, Brazil) , where he has initiated a pioneer thoracic robotic program, remodeled the bronchoscopy center and started the first lung CT screening program in Brazil.

Dr. Santos has published numerous articles on lung and esophageal cancer treatment with an emphasis on minimally invasive surgery as well as innovative surgical technologies such as radiofrequency ablation, interventional bronchoscopy, video-assisted and robotic surgery; and lung transplantation for end stage lung disease.

Dr. Santos is an international member of the Society of Thoracic Surgeons, the Brazilian Society of Pulmonary Physicians, as well as a member of Brazilian and Latin American medical societies. He is fluent in Portuguese, English and Spanish, and has been involved in the leadership of Lung Cancer Initiatives for prevention and early cancer detection in Brazil.

Currently, he is staff surgeon and director at “Instituto Tórax”, a private specialized chest clinic located at Hospital Albert Einstein.

Dr. Edgardo Santos

About Dr. Edgardo Santos

Biography coming soon.

Dr. Giorgio Scagliotti
University of Torino, Italy

About Dr. Giorgio Vittorio Scagliotti

Dr. Scagliotti is currently Professor of Oncology at the University of Torino. Dr. Scagliotti earned his medical degree and completed the postgraduate training in Respiratory Medicine, Internal Medicine, and Medical Oncology at the University of Torino. He is currently chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), Head of the Department of Oncology at University of Torino. Dr. Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. From 2003-07 Executive Board member of the International Association for the Study of Lung Cancer. He is Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 280 publications in peer-reviewed journals and he is the International Editor of the 4th Edition of “Lung Cancer : Principles and practice” and co-editor of the IASLC textbook of multidisciplinary approach to thoracic Oncology.

Dr. Hector Tapia

About Dr. Hector Tapi

Biography coming soon.

Dr. Francisco Tarrazzi

About Dr. Francisco Tarrazzi

Biography coming soon.

Associate Professor Luis Ubillos
Hospital de Clinicas , Uruguay

About Associate Professor Luis Ubillos

Medical School-University Universidad de la Republica, Montevideo, Uruguay. July 2005
Medical Oncology. Universidad de la Republica, Montevideo, Uruguay. May 2010
PhD. Universidad de la Republica, Montevideo, Uruguay. December 2015
MSc. Universidad de la Republica, Montevideo, Uruguay. October 2006

Dr Luis Ubillos is an Associate Professor of Medical Oncology at Hospital de Clinicas in Montevideo, Uruguay. He joined the University in 2010, as associate profesor in medical oncology.

He devotes her time between clinical, teaching and research activities. His research interests are immunotherapy in traslational research, lung cancer, GI Cancer and palliative care. He is committed to global education and actively collaborates with ASCO in educational activities around the world in countries like: Bolivia, Argentina and Chile, and have organized activities in Uruguay.

Dr. Carlos Vallejos

About Dr. Carlos Vallejos

El Dr. Carlos Vallejos es Presidente de la Sociedad Latinoamericana y del Caribe de Oncología Médica (SLACOM). Ocupo este cargo desde setiembre del 2011 y, en la actualidad, pertenece a más 26 sociedades de Oncología. Fue Director General del Instituto Nacional de Enfermedades Neoplásicas, de enero del 2002 a julio del 2006, y se desempeñó como jefe institucional de dicho instituto del 2008 al 2012. Fue Ministro en la cartera de Salud desde julio de 2006 hasta diciembre de 2007. Más tarde se desempeñó como Presidente del Comité Permanente del Plan de Descentralización de la Atención Médica Oncológica a nivel nacional desde diciembre del 2002 hasta el 2005. Actualmente, es Representante Regional para América del Sur de la European Society for Medical Oncology (ESMO) e integrante del Consejo Ejecutivo de la Organización Mundial de la Salud desde mayo de 2007 hasta enero de 2010. También es miembro de la Comisión de Asuntos Internaciones (IAC) de la American Society of Clinical Oncology (ASCO) desde Julio de 2010 y, en noviembre de ese año, Presidente del grupo de Terapia Molecular Específica de Cáncer de la ESMO. El Dr. Vallejos ha participado en 169 investigaciones relacionadas a la oncología, como resultado de ello, tiene más de 60 publicaciones en las revistas de mayor prestigio y ha presentado alrededor de 118 resumenes. Fue ponente en más de 160 eventos nacionales y 82 ponencias internacionales. Por sus grandes logros, ha obtenido más de 46 premios y reconocimientos académicos y profesionales entre ellos destacan:
• Premio Latinoamericano de Oncología – 2011, organizado por Novartis.
• Medalla de Honor del Congreso de la República en el grado “Gran Comandante”.
• Distinción al mejor alumno del MD Anderson Cáncer Center.

Professor Johan Vansteenkiste
Catholic University Leuven and University Hospital Gasthuisberg, Belgium

About Professor Johan Vansteenkiste

Johan Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit / Clinical Trial Unit at the Leuven University Hospital. He studied Medicine in Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, and in Respiratory Endoscopy at the Laser Centre in Marseille, before gaining his PhD at the University of Leuven in 1996. He is an active member of international societies such as ESMO, IASLC, ASCO, ERS and others. He was Secretary of the ERS Thoracic Oncology Assembly and member of the ERS School Board in 2009-2012. He was on the Board of Directors of IASLC in 2009-2013. He is member of the ESMO Lung Educational Group and Guidelines Group, and chaired the European Lung Cancer Conference in March 2015. He is the principal investigator or co-investigator in clinical trials in the area of lung cancer. He is Associate Editor at Annals of Oncology, member of the editorial board of several other journals, and author or co-author of more than 250 peer-reviewed papers and book chapters on Respiratory Oncology.

Professor Marileila Varella-Garcia
University of Colorado Anschutz Medical Campus, USA

About Professor Marileila Varella-Garcia

Marileila Varella Garcia obtained her PhD in Human Genetics in the University of Sao Paulo, Brazil and from her initial career has focused on medical cytogenetics. Soon after a post-doc fellowship in molecular genetics, she started working with fluorescence in situ hybridization (FISH) and implementing this technology in the most challenging biological samples, the formalin-fixed solid tumors. She is a professor at the University of Colorado for over two decades, where she developed a unique expertise to build standard and special probe designs, validate novel reagents, and standardize scoring systems. She has contributed significantly to the detection of sub-clinical tumorigenesis in lung cancer, using minimally invasive assays in sputum. Her translational research focus has also impacted the efficient identification of lung cancer patients likely to benefit from targeted therapies, including tyrosine kinase inhibitors and antibodies. Dr. Varella-Garcia has published more than 250 articles in peer-reviewed journals and has been invited to present in numerous international meetings. She directs the FISH sections in the diagnostic laboratory of the University of Colorado and in the Cancer Center Molecular Pathology Shared Resource. She has also strong interest in educational activities, and is active both in the Colorado Cancer Center and in the IASLC.

Dr. Ruth Vergara

About Dr. Ruth Vergara

I born in Panama. In 1997, I graduated of Medicine at the University of Panama and ended residency in the speacialty of Pathology. I worked during 2 years in Hospital Dr. Joaquin Franco in Las Tablas, then in 2006 started to work in the hospital in Cancer of Panama: Instituto Oncologico Nacional (ION). Working with emphasis in Neuroendocrine Tumors since 2006. Since 2013, I am a Chief of Pathology in the hospital ION.  Others trainning:  1999: Postgraduate degree in higher Teaching. 2007: Distance Course “Introduction to Molecular Biology: from laboratory to Clinical Practice” 2013: Biomarkers in Oncology. Active member of the Panamanian Association of Pathology. I held different positions within the board and was president in 2013.

Dr. Tatiana Vidaurre
National Institute of Neoplastic Diseases, Peru

About Dr. Tatiana Vidaurre

General Director of Instituto Nacional de Enfermedades Neoplásicas. Professional with a high experience in the healthcare field. With expertise in research and public health. Accredited by the National Cancer Institute (USA) as a main investigator and responsible in Peru’s course on “Principles of Clinical Pharmacology. She promoting continuous training with levels of excellence. Currently she is member active of Global Academic Program of MD Anderson Cancer Center of Houston, Texas; and of South West Oncology Group of USA. She is the author of several publications and speaker at academic and scientific events. Professionally belonging to various scientific societies, such as the American Society of Clinical Oncology – ASCO (2010), American Association for Cancer Research – AACR (2009), Mastology Peruvian Society (2004), Peruvian Society for Medical Oncology (2003), European Society for Medical Oncology – ESMO (2003) and Peruvian Society of Oncology (2003), and others.

Dr. Miguel Villalona-Calero
Miami Cancer Institute, USA

About Dr. Miguel Villalona-Calero

A native of the Dominican Republic, Dr. Villalona received his medical degree (magna cum laude) from Universidad Nacional Pedro Henriquez Urena, Dominican Republic. He completed internship and residency in internal medicine at Kings County Hospital Center, State University of New York Health Science Center at Brooklyn. He subsequently completed fellowships in medical oncology at the University of Minnesota Hospitals & Clinics, and Roswell Park Cancer Institute, as well as a fellowship in drug development at the Institute for Drug Development, University of Texas Health Sciences Center at San Antonio.

Dr. Villalona is the Deputy Director and Chief Scientific Officer for the Miami Cancer Institute, as well as Professor of the Department of Medicine, Family Medicine and Community Health, Herbert Wertheim College of Medicine, Florida International University. He was previously the Dorothy M. Davies Chair in Cancer Research, tenured Professor, director of the Division of Medical Oncology and Associate Director for Translational Research at The Ohio State University Comprehensive Cancer Center. He is internationally recognized for his work in the area of developmental therapeutics, testing in patients new anticancer agents or novel combinations.

Dr. Villalona is an Inducted Fellow from the American Association of the Advancement of Science, and has been recognized by the The National Cancer Institute’s (Outstanding Example of Translational Research), the V Foundation (Translational Research Award) and received the Fray Anton de Montesinos award to the most accomplished Dominican Professional in the USA.

Dr. Villalona has participated in 20 federal grants (11 as principal investigator) and has been the principal investigator or co-investigator on a wide variety of cancer research trials funded by the National Cancer Institute, foundations and industry partners. He serves on the National Cancer Institute Clinical Trials Advisory Committee.

Dr. Jonathan Waxman
Boca Raton Regional Hospital, USA

About Dr. Jonathan Waxman

Dr. Waxman obtained his medical degree from the Universidad Anahuac School of Medicine in Mexico City, Mexico. He completed a Residency in General Surgery at Beth Israel Deaconess Medical Center, Harvard Medical School, in Boston Massachusetts. Dr. Waxman completed a Fellowship in Cardiothoracic Surgery at the University of Tennessee Health Center in Memphis Tennessee, and a Fellowship in Minimally Invasive Thoracic Surgery at the University of Pittsburgh Medical Center in Pittsburgh Pennsylvania. Dr Waxman in the medical director of thoracic surgery at Boca Raton regional Hospital.

Dr. Waxman specializes in Minimally Invasive Thoracic Surgery with interests in Video Assisted Thoracoscopic Surgery(VATS), and minimally invasive staging of lung and esophageal disorders, esophageal cancer, and paraesophageal hernia. Dr Waxman is proficient in Transesophageal and Endobronchial Ultrasound (EUS, EBUS) for staging and diagnosis of cancer and mediastinal tumors. He is Board Certified in Cardiothoracic Surgery by the American Board of Thoracic Surgery, and is Board Certified in Surgery by the American Board of Surgery.

Dr. Ignacio Wistuba
M.D. Anderson Cancer Center, USA

About Dr. Ignacio Wistuba

Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, with a joint appointment in Thoracic/Head and Neck Medical Oncology at M.D. Anderson Cancer Center in Houston, TX. He is Director of the Thoracic Molecular Pathology Laboratory, co-leader of the institutional Tissue bank and Pathology Resources, and director of the ECOG-ACRIN Central Biorepository and Pathology Facility. He is a surgical and molecular pathology specialist with a strong record of scientific achievement in lung cancer with over 400 peer-reviewed papers and several book chapters. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for targeted therapy. Dr. Wistuba oversees biomarker studies for lung cancer therapeutic clinical trials, including the MD Anderson BATTLE program, and he is leader of the MD Anderson Cancer Center Support Grant (CCSG) Tissue Biorepository and Pathology Resources (TBPR). He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).

Dr. Antoinette Wozniak

About Dr. Antoinette Wozniak

antoinette-wozniakAntoinette J. Wozniak, MD, FACP is a professor in the Department of Oncology at Wayne State University, School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. She received her MD at the State University of New York at Buffalo, School of Medicine. She did her Internal Medicine Residency at the same institution and a Hematology-Oncology fellowship at the University of Florida. Dr. Wozniak has extensive experience in the treatment of thoracic malignancies. She is an active researcher and has been involved in numerous clinical trials in lung cancer, mesothelioma and early therapeutics. Dr. Wozniak has written over 200 articles, abstracts, and book chapters. She has been the Leader of the Multidisciplinary Thoracic team at the Karmanos Cancer Institute, Fellowship Program Director, President of the Medical Staff, and Division Head for Solid Tumor Oncology. She has served on the Oncology Advisory Committee for the FDA. Dr. Wozniak is an active member of numerous professional organizations including AACR, ASCO, IASLC, a Fellow of the American College of Physicians, the Lung Committee for the Southwest Oncology Group, and a founding member of Free to Breathe

Dr. Nise Yamaguchi

About Dr. Nise Yamaguchi

Biography coming soon.

IASLC Tweets


Facebook Twitter
Switch To Full Site